WAVE Life Sciences (WVE) – Press Releases
-
Wave Life Sciences to Present at Upcoming Investor Conferences
-
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
-
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
-
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
-
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
-
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
-
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
-
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
-
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
-
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
-
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
-
Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023
-
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
-
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
-
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
-
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
-
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
-
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
-
Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
-
Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023
-
Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes
-
Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
-
Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting
-
Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
-
Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023
-
Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023
-
Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
-
Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
-
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
-
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
-
Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
-
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
-
Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference
-
Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference
-
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
-
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
-
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
-
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
-
Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
-
Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
-
Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference
-
Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference
-
Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022
-
Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022
-
Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses
-
Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses
-
Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event
Back to WVE Stock Lookup
